The leukemic progression of MDS cases was driven by the unfavorable prognostic impact of TP53 gene mutation in association with the deletion of chromosome 5 [del(5q)] and potentially the acquisition of RUNX1 gene mutation [77]. This evidence concerns the gene TP53 and myelodysplastic syndrome.